Oncology
Latest news
826 articles · 20 / page
Uneven Progress: US Central Nervous System Cancer Burden 1990–2021 — Stable Incidence, Falling Mortality, Persistent Geographic and Socioeconomic Disparities
GBD 2021 analysis shows stable overall CNS cancer incidence in the US from 1990–2021, with significant declines in mortality and DALYs but major state-level, age, sex, and SDI-related disparities that demand targeted public-health and clini
Boosting Mammogram Screening Rates: What Really Works for Overdue Women?
A Singapore trial shows simple mailed reminders effectively increase overdue mammogram screenings; additional incentives or digital interventions offer no significant benefit.
Ramantamig (JNJ-79635322): A Trispecific T‑Cell Engager Targeting BCMA and GPRC5D Shows Potent Preclinical Activity in Multiple Myeloma
Ramantamig (JNJ-79635322), a trispecific antibody that engages BCMA, GPRC5D and CD3, demonstrates sub-nanomolar cytotoxicity, ex vivo depletion of patient plasma cells, and antitumor activity in xenograft models—supporting ongoing phase 1 t
Metformin in Metastatic Hormone-Sensitive Prostate Cancer Undergoing Androgen Deprivation Therapy: Insights from the STAMPEDE Phase 3 Trial and Contemporary Evidence
Comprehensive review of metformin’s role in metastatic prostate cancer with ADT highlights STAMPEDE trial’s findings: no significant overall survival benefit but metabolic side-effect mitigation. Integration of other RCTs outlines nuanced e
Age‑Adapted Chemotherapy Plus MRD‑Directed Transplantation Improves Safety Without Sacrificing Efficacy in Ph‑Negative Adult ALL: Key Findings from GRAALL‑2014
The GRAALL‑2014 trial shows that age‑adapted chemotherapy with MRD‑guided alloHSCT reduces early mortality and transplant use while maintaining disease‑free survival in adults (18–59) with Ph‑negative ALL; 4‑year DFS was 57.1% and overall s
The Power of Persistence: How Consistent Moderate Exercise Significantly Lowers Digestive Cancer Risk
A Harvard study following 230,000 people over 32 years shows that regular, moderate exercise sustained over time is more effective at preventing digestive system cancers than sporadic high-intensity workouts.
Laparoscopic Distal Gastrectomy Is Comparable to Open Surgery for Clinical T4a Gastric Cancer in Short-Term Outcomes: Results from the UMC‑UPPERGI‑01 RCT
The UMC‑UPPERGI‑01 randomized trial (n=208) found laparoscopic distal gastrectomy with D2 lymphadenectomy had similar 30‑day morbidity and mortality to open surgery for clinical T4a gastric cancer, despite longer operative times and modestl
RNA Cancer Vaccines: Revolutionary Advances Bringing Hope for 2029 Clinical Use
RNA cancer vaccines are emerging as powerful tools against hard-to-treat cancers, with breakthroughs in melanoma, pancreatic, and brain cancers showing promise for widespread clinical adoption by 2029.
Managing Heart Risk from Cancer Immunotherapy: The International Cardio-Oncology Society Position on ICI-Associated Cardiovascular Toxicity
An expert summary of the 2025 ICS position statement on immune checkpoint inhibitor–associated cardiovascular toxic effects, with practical diagnostic and treatment guidance for clinicians and researchers.
Circulating Tumor DNA-Guided Adjuvant Therapy: Recent Advances and Clinical Implications (2021–2025)
This review synthesizes recent evidence (2021–2025) on circulating tumor DNA-guided adjuvant therapy, highlighting advances in personalized cancer management and emerging challenges.
ctDNA-Guided Adjuvant Therapy in Stage III Colon Cancer: DYNAMIC-III Validates Prognosis but Questions Intensification
The randomized phase 2/3 DYNAMIC-III trial shows that postoperative circulating tumor DNA (ctDNA) strongly stratifies recurrence risk in stage III colon cancer. ctDNA-guided de-escalation reduced oxaliplatin exposure and hospitalizations wi
Dual TIGIT/PD‑1 Blockade with Domvanalimab + Zimberelimab Plus FOLFOX Shows Promising Activity in First‑Line Advanced Gastric and GEJ Adenocarcinoma
A phase 2 arm of the EDGE‑Gastric trial reports a 59% confirmed objective response rate and median PFS 12.9 months with domvanalimab (anti‑TIGIT) plus zimberelimab (anti‑PD‑1) combined with FOLFOX in untreated HER2‑negative advanced gastric
ctDNA-Guided Adjuvant Therapy in Stage III Colon Cancer: Prognostic Validation but No Benefit from Chemotherapy Intensification — Key Findings from the DYNAMIC-III Randomized Phase 2/3 Trial
The DYNAMIC-III trial validates circulating tumor DNA (ctDNA) as a strong prognostic marker in stage III colon cancer. ctDNA-guided de-escalation reduced oxaliplatin exposure and hospitalizations with near-standard outcomes, but escalation
Dual TIGIT and PD‑1 Blockade with Domvanalimab + Zimberelimab plus FOLFOX Shows Promising Activity in First‑Line Advanced HER2‑Negative Gastroesophageal Adenocarcinoma
In a phase 2 cohort (EDGE‑Gastric A1), domvanalimab (anti‑TIGIT) plus zimberelimab (anti‑PD‑1) combined with FOLFOX produced a 59% ORR, median PFS 12.9 months and median OS 26.7 months in 41 previously untreated HER2‑negative gastroesophage
Perioperative Pembrolizumab + Trastuzumab with FLOT Achieves High pCR and Feasible Safety in HER2‑Positive Localized Esophagogastric Adenocarcinoma: Interim PHERFLOT Results
Interim results from the phase 2 PHERFLOT trial show a 48.4% pathological complete response and a 67.7% major pathologic response after four cycles of pembrolizumab, trastuzumab and FLOT in localized HER2‑positive esophagogastric adenocarci
First-in-Human VT3989 Shows Early Activity in Mesothelioma — First Clinical Proof of Concept for Targeting Hippo–YAP–TEAD
VT3989, an oral TEAD palmitoylation inhibitor, produced objective responses in refractory mesothelioma with manageable toxicity and establishes first clinical proof of concept for targeting the Hippo–YAP–TEAD pathway.
DESTINY-Breast04 Consolidated: Trastuzumab Deruxtecan Improves Survival and Maintains Quality of Life in HER2‑Low Metastatic Breast Cancer
DESTINY‑Breast04 shows trastuzumab deruxtecan (T‑DXd) significantly improves progression‑free and overall survival vs physician’s choice chemotherapy in HER2‑low metastatic breast cancer, with manageable safety and preserved patient‑reporte
Niraparib Plus Abiraterone Significantly Improves rPFS in HRR‑Deficient mCSPC: AMPLITUDE Phase 3 Results
The AMPLITUDE phase 3 trial shows adding niraparib to abiraterone‑prednisone improves radiographic progression‑free survival in HRR‑deficient metastatic castration‑sensitive prostate cancer, with greater benefit in BRCA‑altered disease but
MAGNITUDE final analyses: Niraparib + Abiraterone improves symptoms and delays chemotherapy but not overall survival in HRR‑altered mCRPC
Final MAGNITUDE results show niraparib combined with abiraterone–prednisone improves radiographic PFS, time to symptomatic progression and delays cytotoxic chemotherapy in HRR‑altered mCRPC (notably BRCA1/2), preserves patient‑reported qual
Neoadjuvant Nivolumab With or Without Low‑Dose Ipilimumab Produces High Pathologic Response and Organ Preservation in Resectable Cutaneous Squamous Cell Carcinoma: Results from the MATISSE Phase 2 Trial
The randomized MATISSE trial shows neoadjuvant nivolumab ± low‑dose ipilimumab yields high major/partial pathological response rates, excellent 2‑year disease‑specific survival, and enables organ preservation in many patients with resectabl
Browse by specialty
Open language-specific specialty feeds and department pages.